Pan-Cancer Analysis Identifies CCDC51 as a Potential Biomarker for Liver
Hepatocellular Carcinoma
Abstract
Background: Coiled coil domain containing protein 51 (CCDC51), as the
two transmembrane helical domains protein, little is known about the
function of it in human cancer. Methods: TCGA, GEPIA, cBioPortal, GTEx,
and TIMER were employed to analyze expression, immune cells
infiltration, prognostic value, genetic alteration, cancer patients’
mutation burden, stem cell stability, and microsatellite instability of
CCDC51 . Results: Decreased CCDC51 expression significantly related with
poor overall survival (OS) of acute myeloid leukemia (LAML),
adrenocortical carcinoma (ACC), glioma (GBMLGG), kidney chromophobe
(KICH), liver hepatocellular carcinoma (LIHC), lung squamous cell
carcinoma (LUSC), skin cutaneous melanoma (SKCM) and uveal melanoma
(UVM), lung adenocarcinoma (LUAD), disease-specific survival (DSS) of
ACC, GBMLGG, SKCM and UVM, and progression-free interval (PFI) of ACC,
KICH and pancreatic adenocarcinoma, squamous cell carcinoma of the head
and neck (HNSC). In human cancer, immune cell infiltration, and tumor
microenvironment, CCDC51 expression is associated with MSI, RNA
modifications, and diverse cancer drug sensitivity. There is potential
for it to be an independent factor contributing to OS in LIHC. CCDC51
was an independent factor for LIHC prognosis in Cox regression and
nomogram analysis. The results of the the Kyoto Encyclopedia of Genes
and Gene Ontology and Genomes indicated that CCDC51 was involved in
aminoacyl-tRNA biosynthesis, RNA transport, colorectal cancer, Wnt
signaling pathway, mismatch repair, mitochondrion, pseudo uridine
synthase activity, mRNA processing, mitochondrial matrix, regulation of
mRNA stability, and mitochondrial inner membrane. Conclusion: Our
research can provide new-insights for LIHC prognostic biomarkers of
CCDC51.